Deep knowledge on
small-molecule drugs and
the 90,000 global patents
covering them

Start your free trial now

Instant access. No credit card. No commitment.

Plans and Pricing

DrugPatentWatch Ultimate Plan Preview

Details for Generic Name: orlistat

« Back to Dashboard
Orlistat is the generic ingredient in two branded drugs marketed by Glaxosmithkline Cons and Hoffmann La Roche, and is included in two NDAs. There are two patents protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.

This ingredient has thirty-eight patent family members in thirty-three countries.

There are nine drug master file entries for orlistat. Three suppliers are listed for this compound.

Summary for Generic Name: orlistat

Tradenames:2
Patents:2
Applicants:2
NDAs:2
Drug Master File Entries: see list9
Suppliers: see list3
Formulation / Manufacturing:see details

Pharmacology for Ingredient: orlistat

Clinical Trials for: orlistat

Meta-analysis of Orlistat Laboratory Data From Placebo-controlled Clinical Trials
Status: Completed Condition: Obesity

Study of Fat Malabsorption by Lipiblock Versus Xenical
Status: Completed Condition: Obesity

Orlistat Induced Modulation on the Fatty Acid Composition in Obese Females
Status: Completed Condition: Overweight

Phase 2 Study of Orlistat and SLx-4090 for the Treatment of Type 1 Hyperlipoproteinemia
Status: Not yet recruiting Condition: Type 1 Hyperlipoproteinemia

Adding Guided Self-Help Group Therapy to the Alli Weight Loss Program in Treating Binge Eating Disorder
Status: Completed Condition: Overweight; Eating Disorders

A Study to Assess the Pharmacologic Equivalence of Two Orlistat Dosage Forms
Status: Completed Condition: Overweight

The Effect of Modified Sham Feeding With Orlistat in Overweight and Obese Subjects
Status: Withdrawn Condition: Overweight

Metformin Versus Orlistat in Obese Polycystic Ovary Syndrome (PCOS) Patients
Status: Completed Condition: Obesity

A Low-Carbohydrate, Ketogenic Diet Versus Orlistat for Weight Loss
Status: Completed Condition: Diabetes Mellitus; Obesity

Assess the Additional Weight Loss Effect of Orlistat Used in Combination With Sibutramine
Status: Completed Condition: Obesity

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Hoffmann La Roche
XENICAL
orlistat
CAPSULE;ORAL020766-001Apr 23, 1999RXYes6,004,996*PED<disabled>Y<disabled>
Glaxosmithkline Cons
ALLI
orlistat
CAPSULE;ORAL021887-001Feb 7, 2007OTCYes6,004,996<disabled>Y<disabled>
This preview shows a limited data set
Subscribe for full access, or try a free trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: orlistat

Country Document Number Publication Date
Poland330972Jun 21, 1999
Taiwan533082May 21, 2003
Hungary0001468May 28, 2000
Israel126902Sep 22, 1999
Hungary0001468Sep 28, 2000
This preview shows a limited data set
Subscribe for full access, or try a free trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000   2001   2002   2003   2004   2005   2006   2007   2008   2009   2010   2011   2012   2013   2014  

For more information try a free trial or see the plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2015 thinkBiotech LLC
ISSN: 2162-2639

Preferred citation:

Friedman, Y. Location of pharmaceutical innovation: 2000–2009 Nature Reviews Drug Discovery 9, 835–836 (2010).

Connect with Social Media:

Follow DrugPatentWatch on Twitter
Connect with DrugPatentWatch on Linkedin
Drug Patents on LinkedIn
`abc